These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33603751)

  • 1. Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance.
    Chen J; Cao X; Li B; Zhao Z; Chen S; Lai SWT; Muend SA; Nossa GK; Wang L; Guo W; Ye J; Lee PP; Feng M
    Front Immunol; 2020; 11():621757. PubMed ID: 33603751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
    Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
    Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously.
    Luo W; Hoang H; Miller KE; Zhu H; Xu S; Mo X; Garfinkle EAR; Costello H; Wijeratne S; Chemnitz W; Gandhi R; Liao Y; Ayello J; Gardenswartz A; Rosenblum JM; Cassady KA; Mardis ER; Lee DA; Cripe TP; Cairo MS
    J Exp Clin Cancer Res; 2024 Jul; 43(1):193. PubMed ID: 38992659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
    Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
    Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
    Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
    Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy.
    Zhang YR; Luo JQ; Zhang JY; Miao WM; Wu JS; Huang H; Tong QS; Shen S; Leong KW; Du JZ; Wang J
    Small; 2020 Nov; 16(46):e2004240. PubMed ID: 33107142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of miR-340 controls pancreatic cancer cell
    Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors.
    Li D; Xiong W; Wang Y; Feng J; He Y; Du J; Wang J; Yang M; Zeng H; Yang YG; Wu N; Chen S; Dong Z
    Sci Immunol; 2022 Jan; 7(67):eabj5501. PubMed ID: 35061505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
    Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
    Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
    Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
    Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
    Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
    Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precise Delivery of Nanomedicines to M2 Macrophages by Combining "Eat Me/Don't Eat Me" Signals and Its Anticancer Application.
    Tang Y; Tang Z; Li P; Tang K; Ma Z; Wang Y; Wang X; Li C
    ACS Nano; 2021 Nov; 15(11):18100-18112. PubMed ID: 34751571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.
    Zhang M; Hutter G; Kahn SA; Azad TD; Gholamin S; Xu CY; Liu J; Achrol AS; Richard C; Sommerkamp P; Schoen MK; McCracken MN; Majeti R; Weissman I; Mitra SS; Cheshier SH
    PLoS One; 2016; 11(4):e0153550. PubMed ID: 27092773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy.
    Ramesh A; Kumar S; Nguyen A; Brouillard A; Kulkarni A
    Nanoscale; 2020 Jan; 12(3):1875-1885. PubMed ID: 31903467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
    Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN
    PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.